1.63
Boundless Bio Inc Aktie (BOLD) Neueste Nachrichten
12 Health Care Stocks Moving In Tuesday's Intraday SessionAdagio Medical Holdings (NASDAQ:ADGM), Allog - Benzinga
Tuesday's session: gap up and gap down stocks - ChartMill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Boundless Bio, Inc. Files Form 8-K with SEC – Corporate Details, Nasdaq Listing, and Emerging Growth Company Status - Minichart
Boundless Bio to terminate San Diego lease, agrees to $10 million payment - Investing.com Australia
Boundless Bio Terminates Major Long-Term San Diego Lease - TipRanks
Boundless Bio (NASDAQ: BOLD) pays $10M to exit long-term lab lease - Stock Titan
Chipmakers Recap: Is Boundless Bio Inc in a long term uptrend2026 Buyback Activity & Consistent Income Trade Ideas - baoquankhu1.vn
GODN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
EPS Watch: Is Boundless Bio Inc subject to activist investor interest2026 Volume Leaders & Safe Entry Point Alerts - baoquankhu1.vn
Aug Decliners: What hedge funds are buying Akanda Corp2026 Price Targets & Weekly High Potential Stock Alerts - baoquankhu1.vn
PMN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Swing Trade: Is EFOI forming higher highs and higher lows2026 Momentum & Weekly Momentum Stock Picks - baoquankhu1.vn
JSPR Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
NVNO PE Ratio & Valuation, Is NVNO Overvalued - Intellectia AI
BOLD PE Ratio & Valuation, Is BOLD Overvalued - Intellectia AI
CUE.O PE Ratio & Valuation, Is CUE.O Overvalued - Intellectia AI
LIXT PE Ratio & Valuation, Is LIXT Overvalued - Intellectia AI
Stock List: Research Stocks from Around the World - GuruFocus
APUS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Volume Recap: Will Boundless Bio Inc face regulatory challenges2026 WrapUp & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
If You Invested $1,000 in Neuphoria Therapeutics Inc (NEUP) - Stock Titan
USA Stocks: Research Stocks from USA Stock Market - GuruFocus
What analysts say about Boundless Bio Inc stockPortfolio Gains Report & Reliable Intraday Trade Plans - baoquankhu1.vn
Checkpoint Inhibitors Competitive Landscape & Pipeline 2026: Emerging Therapies, ROA, Molecules, Companies and Future Outlook - Barchart
Checkpoint Inhibitors Competitive Landscape & Pipeline 2026: - openPR.com
Stop Loss: Can Boundless Bio Inc ride the EV wave2026 Gainers & Long Hold Capital Preservation Plans - baoquankhu1.vn
If You Invested $1,000 in Rallybio Corp (RLYB) - Stock Titan
If You Invested $1,000 in SeaStar Medical Holding Corp (ICU) - Stock Titan
BOLD Technical Analysis & Stock Price Forecast - Intellectia AI
MRKR PE Ratio & Valuation, Is MRKR Overvalued - Intellectia AI
Boundless Bio: Underestimated Biotech With First-In-Class EcDNA Targeted Kinesin Degrader - Seeking Alpha
Risks Report: Is Boundless Bio Inc stock a smart retirement pick2026 Price Momentum & Technical Confirmation Trade Alerts - baoquankhu1.vn
Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026 - The Manila Times
Inside a novel cancer drug aiming at ecDNA-positive, high-risk breast tumors - Stock Titan
Bear Alert: Can Boundless Bio Inc ride the EV waveInsider Buying & Weekly Momentum Picks - baoquankhu1.vn
Trend Review: Can Boundless Bio Inc maintain its current growth rateWeekly Trade Recap & Weekly High Return Stock Opportunities - baoquankhu1.vn
FORTY Should I Buy - Intellectia AI
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
02386 Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Gains Report: What are the analyst revisions for Boundless Bio IncIs RAAQU stock a good investment in YEARWeekly Profit Report & Free Reliable Trade Execution Plans - baoquankhu1.vn
ASTI Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Boundless Bio posts smaller-than-expected Q4 loss - MSN
CVU Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
AHRT Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Leerink reiterates Market Perform on Boundless Bio stock at $4 - Investing.com
Boundless Bio Reports Q4 and Full Year 2025 Financial Results, Highlights Progress of KOMODO-1 Clinical Trial and BBI-940 Program - Minichart
03268 Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
02400 Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
MGRD Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Boundless Bio (BOLD) Posts First Revenue of $17.3M, Narrows Q4 Loss to $0.58/Share - AlphaStreet
Bold Biosciences 2025 10-K: ecDNA-Enabled Cancer Drug Development, Spyglass Platform & BBI-940 Kinesin Degrader Overview - Minichart
Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - Bitget
Boundless Bio beats fourth quarter loss estimates By Investing.com - Investing.com Canada
Boundless Bio 10-K: $0 Revenue, $(58.2)M Net Loss, $(63.6)M Operating Loss - TradingView
Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - GlobeNewswire Inc.
Exit Recap: Is Boundless Bio Inc stock a smart retirement pickEarnings Summary Report & AI Enhanced Trading Signals - baoquankhu1.vn
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):